![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1384302
¼¼°è À¯ÀüÀÚ ¿¹Ãø Åø ½ÃÀå : ÄÄÆ÷³ÍÆ®º°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2023-2032³â)Gene Prediction Tools Market-By Component (Software, Service), Application (Drug Discovery & Designing, Diagnostics), End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospital & Clinics), Global Forecast (2023-2032) |
À¯ÀüÀÚ ¿¹Ãø Åø ½ÃÀå ±Ô¸ð´Â Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí À¯Àü°ú Áúº´ÀÇ º¹ÀâÇÑ °ü°è¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁü¿¡ µû¶ó 2023³â¿¡¼ 2032³â¿¡ °ÉÃÄ ¾à 18%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¬±¸ÀÚ°¡ Àΰ£ °Ô³ðÀ» ´õ ±íÀÌ ÆÄ°íµé¸é¼, °í±Þ À¯ÀüÀÚ ¿¹Ãø ÅøÀÇ Çʿ伺ÀÌ °¡Àå Áß¿äÇØÁý´Ï´Ù.
³ôÀº 󸮷® ½ÃÄö½Ì ±â¼ú, ÀΰøÁö´É, ¸Ó½Å·¯´×ÀÇ À¶ÇÕÀº À¯ÀüÀÚÀÇ ±â´ÉÀ» Á¤È®ÇÏ°Ô ¿¹ÃøÇϰí ÀáÀçÀû Áúº´À» ÀÏÀ¸Å°´Â µ¹¿¬º¯À̸¦ È®ÀÎÇÒ ¼ö ÀÖ´Â Á¤±³ÇÑ µµ±¸ °³¹ßÀ» µÞ¹ÞħÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, DNA ½ÃÄö½ÌÀÇ ¼¼°è ¸®´õÀÎ Illumina Inc.´Â 2023³â 6¿ù ¿ÏÀüÈ÷ »õ·Î¿î PrimateAI-3D Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ AI ¾Ë°í¸®ÁòÀº ȯÀÚÀÇ Áúº´À» À¯¹ßÇÏ´Â À¯ÀüÀÚ º¯À̸¦ ¿¹ÃøÇÕ´Ï´Ù. ÀÌ ±â¼úÀû ½Ã³ÊÁö È¿°ú°¡ °ß°íÇÑ »ýŰ踦 Ű¿ì°í À¯ÀüÀÚ ¿¹Ãø Åø ½ÃÀåÀ» Àü·Ê¾ø´Â ³ôÀÌ·Î ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.
À¯ÀüÀÚ ¿¹Ãø Åø ½ÃÀåÀº ±¸¼º ¿ä¼Ò, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
¼ºñ½º ÄÄÆ÷³ÍÆ® ºÎ¹®Àº 2032³â±îÁö Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô³ð µ¥ÀÌÅÍÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬±¸ÀÚ¿Í »ý¸í°øÇÐ ±â¾÷Àº µ¥ÀÌÅÍ ºÐ¼® ¹× ÇØ¼®À» À§ÇØ Àü¹® ¼ºñ½º Á¦°ø¾÷ü¸¦ Ȱ¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºñ½º¿¡´Â ±â´É ¾î³ëÅ×À̼Ç, ÆÐ½º¿þÀÌ ºÐ¼®, º¯Çü ¿ì¼±¼øÀ§ ÁöÁ¤ µî ´Ù¾çÇÑ ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¼ºñ½º¸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº ÀÌ ºÐ¾ßÀÇ Àü¹®°¡ÀÇ Àü¹® Áö½ÄÀ» Ȱ¿ëÇÏ¿© ¹æ´ëÇÑ °Ô³ð µ¥ÀÌÅͼ¼Æ®¿¡¼ ÀÇ¹Ì ÀÖ´Â ÅëÂû·ÂÀ» µµÃâÇÒ ¼ö ÀÖ¾î ¼ºñ½º ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
Áø´Ü ºÐ¾ß´Â ´Ù¾çÇÑ Áúº´°ú °ü·ÃµÈ À¯ÀüÀÚ ¸¶Ä¿¸¦ È®ÀÎÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, 2023³âºÎÅÍ 2032³â±îÁö °ÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÇ·á Á¦°ø¾÷ü´Â Áúº´ÀÇ Á¶±â ¹ß°ß ¹× °³ÀÎÈ Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô ÇÏ´Â ÀÌ·¯ÇÑ µµ±¸ÀÇ ÀáÀç·ÂÀ» ÀνÄÇϰí Àֱ⠶§¹®¿¡ Áø´Ü¿ë À¯ÀüÀÚ ¿¹Ãø ÅøÀÇ Ã¤¿ëÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. °Ô³ð µ¥ÀÌÅÍÀÇ ÇØ¼® ¹× ÇØ¼® ´É·ÂÀº Áúº´ ¼ÒÀÎÀÇ È®ÀÎÀ» µ½°í ¿¹¹æÀûÀÌ°í °³º°ÈµÈ °Ç° °ü¸®·ÎÀÇ ÆÐ·¯´ÙÀÓ À̵¿À» ÃËÁøÇÕ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯ÀüÀÚ ¿¹Ãø Åø ½ÃÀåÀº À¯ÀüüÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó ¼ºÀå µîÀ» ¹è°æÀ¸·Î 2032³â±îÁö ¸·´ëÇÑ ¼öÀÍÀ» ¿Ã¸± °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Áß±¹, ÀϺ», Àεµ µî ±¹°¡ÀÇ Á¤ºÎ ¹× ¹Î°£ ´Üü´Â Àü¹ÝÀûÀÎ °Ç° °ü¸® »óȲÀ» °³¼±Çϱâ À§ÇØ °Ô³ð ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¸¦ Àû±ØÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿äÀÎÀº ÀÌ·¯ÇÑ µµ±¸ÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÇ Çâ»ó°ú ÇÔ²²ÀÌ Áö¿ª ½ÃÀå Àü¸ÁÀ» ±àÁ¤ÀûÀ¸·Î Èçµé°í ÀÖ½À´Ï´Ù.
Gene prediction tools market size is predicted to witness around 18% CAGR from 2023 to 2032 due to the escalating demand for precision medicine and the growing understanding of the intricate relationship between genetics and disease. As researchers delve deeper into the human genome, the need for advanced gene prediction tools becomes paramount.
The convergence of high-throughput sequencing technologies, artificial intelligence, and machine learning is propelling the development of sophisticated tools that can accurately predict gene functions and identify potential disease-causing mutations. For instance, in June 2023, Illumina Inc., a global leader in DNA sequencing announced the launch of the all new PrimateAI-3D. This AI algorithm predicts the disease-causing genetic mutation in patients. This technological synergy is fostering a robust ecosystem, propelling the gene prediction tools market to unprecedented heights.
The gene prediction tools market is classified as per component, application, end-user, and region.
The service component segment is expected to witness substantial growth through 2032. As the complexity of genomic data increases, researchers and biotech companies are turning to specialized service providers for data analysis and interpretation. These services encompass a spectrum of offerings, including functional annotation, pathway analysis, and variant prioritization. They allow researchers to leverage the expertise of professionals in the field to derive meaningful insights from vast genomic datasets, thus boosting the demand for service.
The diagnostics segment is anticipated to record strong CAGR from 2023 to 2032 as they become an indispensable part of identifying genetic markers associated with various diseases. The adoption of of gene prediction tools for diagnostics is on a surge as healthcare providers recognize the potential of these tools in enabling early disease detection and personalized treatment strategies. Their ability to analyze and interpret genomic data aids in the identification of disease predispositions, facilitating a paradigm shift towards preventive and personalized healthcare.
Asia Pacific gene prediction tools market will generate massive revenues by 2032 driven by increasing investments in genomics research, rising awareness about personalized medicine, and a growing healthcare infrastructure. Governments and private entities in countries such as China, Japan, and India are actively promoting genomic research initiatives to improve the overall healthcare landscape. This factor, along with improved cognizance pertaining to the benefits of these tools is positively swaying the regional market outlook.